Physician profile
William S Silver
NPI 1720074172
$26,288.70
in general payments reported to CMS, 2019-2025
31 companies · $16K in 2025
The $16K reported for 2025 was more than what 94% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,190 · 2020: $493 · 2021: $1,532 · 2022: $2,556 · 2023: $2,183 · 2024: $2,620 · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $14K · Food and Beverage: $6,798 · Education: $84.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $13,634.52 |
| Food and Beverage | $6,798.00 |
| Education | $84.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $13,634.52 | 2025 | |
| Abbvie INC. | $4,252.15 | 2019-2025 | Skyrizi, Rinvoq, Creon |
| Gilead Sciences, INC. | $1,474.92 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,019.73 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $879.03 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| E.R. Squibb & Sons, L.L.C. | $683.34 | 2021-2024 | Zeposia |
| Madrigal Pharmaceuticals | $604.64 | 2024-2025 | Rezdiffra, Resmetirom |
| Intercept Pharmaceuticals, INC. | $501.41 | 2019-2025 | |
| Janssen Biotech, INC. | $497.48 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Celgene Corporation | $425.06 | 2021-2024 | Zeposia |
| Ardelyx, INC. | $343.12 | 2022-2025 | Ibsrela |
| Braintree Laboratories, INC. | $282.52 | 2023-2025 | Sutab, Suflave |
| Aimmune Therapeutics, INC. | $225.08 | 2024-2025 | Zenpep |
| Pfizer INC. | $194.25 | 2019-2023 | |
| Nestle Healthcare Nutrition INC. | $180.98 | 2021-2023 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $174.73 | 2019-2024 | Dificid |
| Qol Medical, LLC | $152.05 | 2021-2025 | Sucraid, Sucraid |
| Redhill Biopharma INC. | $149.03 | 2021-2022 | |
| Janssen Scientific Affairs, LLC | $122.09 | 2019 | |
| Lilly USA, LLC | $118.49 | 2025 | Omvoh |
| Evoke Pharma, INC. | $105.40 | 2021-2023 | Gimoti |
| Phathom Pharmaceuticals, INC. | $49.02 | 2024-2025 | Voquezna |
| Vivus LLC | $42.29 | 2024-2025 | Pancreaze |
| Alfasigma USA, INC. | $33.62 | 2020-2022 | |
| Ironwood Pharmaceuticals, INC | $30.79 | 2019 | |
| Endo Pharmaceuticals INC. | $23.76 | 2019 | |
| Ucb, INC. | $19.51 | 2019 | |
| Novo Nordisk INC | $19.11 | 2025 | Wegovy |
| Allergan, INC. | $17.24 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $16.81 | 2025 | Iqirvo |
| Ferring Pharmaceuticals INC. | $16.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Silver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.